Rj. Edwards et al., IDENTIFICATION OF THE EPITOPE OF AN ANTIPEPTIDE ANTIBODY WHICH BINDS TO CYP1A2 IN MANY SPECIES INCLUDING MAN, Biochemical pharmacology, 46(2), 1993, pp. 213-220
An anti-peptide antibody was raised against the sequence Thr-Gly-Ala-L
eu-Phe-Lys-His-Ser-Glu-Asn-Tyr-Lys which occurs at positions 283-294 i
n the rat cytochrome P450 enzyme CYP1A2. Compared with its binding to
the peptide used for immunization, the antibody bound with only slight
ly reduced affinity to the truncated peptides Thr-Gly-Ala-Leu-Phe-Lys-
His-Ser and Leu-Phe-Lys-His-Ser. However, binding to the peptide Ser-G
lu-Asn-Tyr-Lys-Asp-Asn, which overlaps with the C-terminal region of t
he immunizing peptide, was very low. Thus, a major epitope for the ant
i-peptide antibody is Leu-Phe-Lys-His-Ser, which corresponds to a regi
on of CYP1A2 that is conserved in many species. The antibody was teste
d by immunoblotting for its ability to bind to hepatic microsomal frac
tions from a number of species. Where possible animals were treated wi
th compounds which induce CYP1A2 and the results compared with those w
ith untreated animals. It was found that the antibody bound to rat, mo
use, rabbit, hamster, guinea pig, pig, marmoset monkey and human CYP1A
2. No evidence was found for binding to dog CYP1A2. The region corresp
onding to the major epitope at residues 286-290 of rat CYP1A2 was iden
tical in mouse, hamster, rabbit and human CYP1A2. The sequence of marm
oset and guinea pig CYP1A2 are not known but.are predicted to be very
similar to the sequence in the rat. The lack of binding of the antibod
y to dog CYP1A2 may be explained by two differences in this region com
pared with rat CYP1A2. Maximum inhibition of CYP1A2 activity by this a
ntibody, as measured by high-affinity phenacetin O-deethylase activity
, was 20%. This is in contrast to a previously described anti-peptide
antibody directed to an adjacent region which caused 65% inhibition of
this activity. Thus, the edge of an inhibitory region on the surface
of cytochrome P450 has been identified. The ability of the antibody to
bind to CYP1A2 from a number of animals should make this antibody of
use for studying the levels of CYP1A2 apoprotein in many species.